secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zeo ScientifiX, Inc. (ZEOX)
CIK:        0001557376
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0001829126-25-008357
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZEO ScientifiX positioned for Florida stem cell market growth after SB 1768 enactment
--------------------------------------------------------------------------------

- Florida SB 1768, effective July 1, 2025, allows physicians to administer non-FDA-approved stem cell therapies for orthopedic, wound care, and pain under cGMP.
- ZEO expects revenue growth from increased physician demand, patient awareness, and medical tourism to Florida.
- Company launched IRB-approved clinical study (PPX™) for musculoskeletal joint pathologies, targeting up to 350 patients; 5 clinics enrolled, 7 patients to date.
- ZEO evaluating lab expansion at Nova Southeastern University for additional clean rooms and research space.
- New law enables collection of real-world safety/outcome data, potentially lowering risks for future FDA submissions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557376/000182912625008357/0001829126-25-008357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557376/000182912625008357/zeoscientifix_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-008357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer